Amyloid Cardiomyopathy
Acoramidis approved to reduce CV death, hospitalization for cardiac amyloidosis
BridgeBio Pharma announced that acoramidis, its small molecule stabilizer of transthyretin, has been approved by the FDA for the reduction of CV death and hospitalization in patients with transthyretin amyloid cardiomyopathy.
‘Sparking hope,’ celebrating a century of heart health advances at AHA 2024
CHICAGO — When the American Heart Association was founded by six clinicians in June 1924, there was no treatment — and little hope — for people living with heart disease.
Phase 3 data show acoramidis improves outcomes in transthyretin amyloid cardiomyopathy
Acoramidis, a treatment for symptomatic transthyretin amyloid cardiomyopathy, was associated with marked improvements in all-cause mortality and CV-related hospitalizations compared with placebo, according to a press release from BridgeBio.
Top in cardiology: Cannabis and CVD risk, survival benefit of Vyndamax
In last week’s top story in cardiology, a cross-sectional analysis found that cannabis use was significantly associated with increased odds of having a high atherosclerotic CVD risk.
Trial of acoramidis for transthyretin amyloid cardiomyopathy misses primary endpoint
In the 12-month topline results of the ATTRibute-CM trial, acoramidis, a treatment for symptomatic transthyretin amyloid cardiomyopathy, did not meet its primary endpoint, BridgeBio Pharma announced.
Making tafamidis cost-effective for TTR amyloid cardiomyopathy may require 93% price reduction
Although tafamidis can provide substantial clinical benefit for patients with transthyretin amyloid cardiomyopathy, the drug exceeds cost-effectiveness thresholds at its current list price of $225,000 per year, according to an analysis published in Circulation.
Part of the Healio Network
Amyloid Cardiomyopathy
Amyloid cardiomyopathy (cardiac amyloidosis) is a form of restrictive cardiomyopathy that can result in significant progressive diastolic congestive heart failure.